Lexeo Therapeutics, Inc. (LXEO) Earnings Call Transcripts

Lexeo Therapeutics, Inc.'s Latest Earnings Call - June 15, 2026

In the second quarter of fiscal year 2026, Lexeo Therapeutics (LXEO:US) provided a significant update on its pivotal study design for LX2006, aimed at treating Friedreich's ataxia (FA). Management announced the finalization of the SUNRISE-FA 2 trial protocol, which will include a concurrent untreated control group, enhancing the study's rigor. While specific revenue and earnings figures were not disclosed, the focus on advancing LX2006 and the anticipated top-line data readout in the second half of 2027 could serve as a catalyst for stock movement, especially given the urgent unmet need in the FA patient population.

Reported metrics

Guidance from management

Management is confident in the trajectory of enrollment for the SUNRISE-FA 2 study and anticipates a top-line data readout in the second half of 2027, with a BLA submission targeted for the first half of 2028.

What management said

No, I think you've covered everything, Nolan. I think the fact that we've seen that elevated troponin level in those patients even who had relatively just mildly LVMI in our Phase I, Phase II data suggests that that data is going to contribute to show that these patients benefit regardless.

Yes. And remember, troponin is an important secondary endpoint, lateral wall thickness is an important secondary endpoint. mFARS is an important secondary endpoint. All of these are independent of the left ventricular mass index level at baseline.

What analysts pressed on

Analysts expressed concerns regarding the potential label for LX2006 and whether it could be restricted based on baseline characteristics of severity. There were also questions about the expected changes in the untreated control group and the implications for the study's power and endpoints.

Main topics on the call

• Finalization of SUNRISE-FA 2 Study Design — Lexeo has finalized the pivotal study protocol for LX2006, which includes a concurrent untreated control group to minimize bias. CEO Nolan Townsend stated, "We believe this study design best positions us to demonstrate m...
• Accelerated Approval Pathway — The study is designed to support an accelerated approval pathway, with a primary endpoint of left ventricular mass index (LVMI) assessed at 6 months. Management indicated they are targeting a BLA submission in the first ...
• Enrollment Progress — Enrollment for the ongoing CLARITY-FA study is progressing well, with more than 60% of participants coming in over the last two months. The first patient from CLARITY-FA is expected to enroll in SUNRISE-FA 2 by the end o...
• Efficacy Data from Phase I/II Trials — In Phase I/II trials, LX2006 demonstrated an 18% reduction in LVMI at 6 months, with higher doses achieving reductions of up to 33%. CMO Nani Bhalla noted, "These improvements are durable and, in many cases, deepen over ...

Read the full Lexeo Therapeutics, Inc. transcript (June 15, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 12 Lexeo Therapeutics, Inc. earnings call transcripts on record, spanning July 15, 2024 to June 29, 2026. Based on this history, Lexeo Therapeutics, Inc. reports quarterly. The most recent call on file is dated June 29, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

LXEO

Exchange

NasdaqGM

Country

US

Sector

Health Care

Industry

Biotechnology

Calls on record

12

First call

July 15, 2024

Most recent

June 29, 2026

Reporting cadence

quarterly